[go: up one dir, main page]

HUP0101369A3 - Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine - Google Patents

Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine

Info

Publication number
HUP0101369A3
HUP0101369A3 HU0101369A HUP0101369A HUP0101369A3 HU P0101369 A3 HUP0101369 A3 HU P0101369A3 HU 0101369 A HU0101369 A HU 0101369A HU P0101369 A HUP0101369 A HU P0101369A HU P0101369 A3 HUP0101369 A3 HU P0101369A3
Authority
HU
Hungary
Prior art keywords
antihistamine
composition
skin diseases
treating respiratory
leukotriene antagonist
Prior art date
Application number
HU0101369A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HUP0101369A2 publication Critical patent/HUP0101369A2/hu
Publication of HUP0101369A3 publication Critical patent/HUP0101369A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HU0101369A 1997-12-23 1998-12-21 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine HUP0101369A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6863897P 1997-12-23 1997-12-23
US7863898P 1998-03-19 1998-03-19
PCT/US1998/026223 WO1999032125A1 (en) 1997-12-23 1998-12-21 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine

Publications (2)

Publication Number Publication Date
HUP0101369A2 HUP0101369A2 (hu) 2002-03-28
HUP0101369A3 true HUP0101369A3 (en) 2002-11-28

Family

ID=26749192

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101369A HUP0101369A3 (en) 1997-12-23 1998-12-21 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine

Country Status (26)

Country Link
EP (1) EP1041990B1 (hu)
JP (2) JP2001526232A (hu)
KR (1) KR100737710B1 (hu)
CN (1) CN1283115A (hu)
AR (1) AR017224A1 (hu)
AT (1) ATE331522T1 (hu)
AU (1) AU758771B2 (hu)
BR (1) BR9814417A (hu)
CA (1) CA2315721C (hu)
CO (1) CO4980868A1 (hu)
CZ (1) CZ301349B6 (hu)
DE (1) DE69835103T2 (hu)
DK (1) DK1041990T3 (hu)
ES (1) ES2263229T3 (hu)
HU (1) HUP0101369A3 (hu)
ID (1) ID26390A (hu)
IL (1) IL136461A0 (hu)
MY (1) MY121744A (hu)
NO (1) NO20003288L (hu)
NZ (1) NZ520907A (hu)
PE (1) PE20000126A1 (hu)
PL (1) PL193131B1 (hu)
PT (1) PT1041990E (hu)
SA (1) SA99200013B1 (hu)
SK (1) SK286103B6 (hu)
WO (1) WO1999032125A1 (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007495A1 (en) 1992-09-03 1994-04-14 Sepracor Inc. Use of norastemizole for the treatment of allergic disorders
US6303632B1 (en) 1992-09-03 2001-10-16 Sepracor Inc. Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6248308B1 (en) * 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
IT1303671B1 (it) 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
EP1000623A1 (en) * 1998-09-29 2000-05-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Use of epinastine as antitussivum
US20020198246A1 (en) 1998-09-30 2002-12-26 Ono Pharmaceutical Co., Ltd. Agent for preventing and/or treating sinusitis
KR100568004B1 (ko) * 1998-09-30 2006-04-07 오노 야꾸힝 고교 가부시키가이샤 부비강염의 예방 및/또는 치료제
CN1213752C (zh) * 2000-02-03 2005-08-10 先灵公司 变应性和炎性疾病的治疗
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
JP2002087963A (ja) * 2000-09-08 2002-03-27 Nippon Boehringer Ingelheim Co Ltd 直接打錠により製造されたエピナスチン含有錠剤
US20020094345A1 (en) 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
PE20020324A1 (es) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
JP4074427B2 (ja) 2000-12-18 2008-04-09 株式会社栃木臨床病理研究所 子宮内膜症の予防又は治療薬
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
BR0210534A (pt) * 2001-06-20 2004-06-22 Schering Corp Anti-histaminas para o tratamento de congestão nasal e obstrução nasal
DE60232445D1 (de) 2001-06-28 2009-07-09 Ucb Farchim Sa Cetirizin und pseudoephedrin enthaltende tablette
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
AU2003237253A1 (en) * 2002-05-29 2003-12-19 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
WO2004004728A1 (en) * 2002-07-02 2004-01-15 Ucb Farchim S.A. Diarylmethylpiperazines as prophylactic or therapeutic agents for viral myocarditis
WO2004052367A1 (en) * 2002-12-06 2004-06-24 Ucb Farchim, S.A. Tablet comprising efletirizine and pseudoephedrine
WO2004087095A2 (es) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositivo osmótico que contiene zafirlukast y un antagonista h1
EP1468696A1 (en) * 2003-04-17 2004-10-20 Boehringer Ingelheim International GmbH Combinations of epinastine and antiphlogisitcs as new pharmaceutical compositions for the treatment of skin diseases
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
EP1735001A2 (en) * 2004-03-24 2006-12-27 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
RU2429844C1 (ru) * 2010-04-12 2011-09-27 Вячеслав Михайлович Провоторов Способ лечения мужчин, больных бронхиальной астмой с ранним приобретенным андрогенодефицитом
US9044479B2 (en) * 2010-06-16 2015-06-02 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
WO2012150707A1 (ja) 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
WO2013058527A2 (ko) * 2011-10-18 2013-04-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제
KR101278572B1 (ko) * 2011-10-18 2013-06-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제
EP2969002B8 (en) 2013-03-13 2018-02-21 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
CN105263579B (zh) 2013-03-13 2020-01-10 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗血管炎中的用途
EP3300734B1 (en) 2013-03-13 2019-08-14 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US9636318B2 (en) * 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
KR102356601B1 (ko) 2014-06-10 2022-01-27 지엘팜텍주식회사 슈도에페드린을 함유하는 방출조절 펠렛 조성물
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US9981039B2 (en) 2015-05-29 2018-05-29 Accolade Pharma Llc Composition, its preparation and method of use in treating skin disorders
MX2018013475A (es) * 2016-05-17 2019-08-12 Proponent Biotech Gmbh Acido carboxilico para tratar/prevenir congestion nasal.
WO2017198701A1 (en) * 2016-05-17 2017-11-23 Proponent Biotech Gmbh Carboxylic acids for treating/preventing a skin disease
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US5276044A (en) * 1991-08-14 1994-01-04 Allergan, Inc. Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
DE4203201A1 (de) * 1992-02-05 1993-08-12 Boehringer Ingelheim Kg Neue amidinderivate, ihre herstellung und verwendung
NZ246593A (en) * 1992-02-05 1997-07-27 Boehringer Ingelheim Int Amidine derivatives; their preparation and medicaments containing them
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
JPH08325265A (ja) * 1995-05-29 1996-12-10 Fujisawa Pharmaceut Co Ltd チアゾリルベンゾフラン誘導体の製造方法、および該製造方法に用いられる化合物
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
NZ331160A (en) * 1996-02-08 2000-07-28 Merck & Co Inc use of loratadine and a leukotriene antagonist to treat asthma
CA2256721A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物

Also Published As

Publication number Publication date
PL193131B1 (pl) 2007-01-31
HUP0101369A2 (hu) 2002-03-28
NZ520907A (en) 2004-05-28
MY121744A (en) 2006-02-28
ID26390A (id) 2000-12-21
CA2315721A1 (en) 1999-07-01
AU758771B2 (en) 2003-03-27
CN1283115A (zh) 2001-02-07
DE69835103T2 (de) 2006-12-21
SK286103B6 (sk) 2008-03-05
ES2263229T3 (es) 2006-12-01
PT1041990E (pt) 2006-10-31
KR100737710B1 (ko) 2007-07-11
JP2011068679A (ja) 2011-04-07
PL341343A1 (en) 2001-04-09
ATE331522T1 (de) 2006-07-15
EP1041990B1 (en) 2006-06-28
CZ301349B6 (cs) 2010-01-27
SK8972000A3 (en) 2001-02-12
WO1999032125A1 (en) 1999-07-01
DK1041990T3 (da) 2006-10-02
HK1027502A1 (en) 2001-01-19
CA2315721C (en) 2008-08-12
NO20003288L (no) 2000-08-22
JP2001526232A (ja) 2001-12-18
AR017224A1 (es) 2001-08-22
DE69835103D1 (de) 2006-08-10
SA99200013B1 (ar) 2006-10-02
KR20010033485A (ko) 2001-04-25
CZ20002198A3 (cs) 2000-11-15
EP1041990A1 (en) 2000-10-11
AU1907199A (en) 1999-07-12
NO20003288D0 (no) 2000-06-22
BR9814417A (pt) 2000-10-10
CO4980868A1 (es) 2000-11-27
PE20000126A1 (es) 2000-02-23
IL136461A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
HUP0101369A3 (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
EP1128832A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND RELATED DISEASES
IL142132A0 (en) Methods and compositions for treating receptor mediated diseases
EP1109580A4 (en) METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES
EP1115286A4 (en) METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
IL136425A0 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
ZA200201819B (en) Preventive and therapeutic agents for eye diseases.
HUT74948A (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
HUP0003478A3 (en) Synergistic fungicidal compositions, their use and process for their preparation
HRP980502B1 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oles, processes for their preparation and their use as medicaments
EP0921803A4 (en) METHOD FOR PREVENTING AND TREATING PESTVIRUS INFECTIONS AND RELATED DISEASES
HUP0203152A3 (en) Method and compositions for treating pulmonary diseases
HUP9600665A2 (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
HUT74745A (en) Pharmaceutical compositions containing p antagonist for treating pruritis, eye- and eyelid-acs and eye-and eyelid dysaesthesia
HUP9904173A3 (en) Pharmaceutical composition for treating viral diseases
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
GB9820631D0 (en) Hair treatment composition, method and use
SG65766A1 (en) Composition for preventing and treating gingival diseases
PL345068A1 (en) Novel compounds derived from α-d-xylose, preparation method and therapeutic use
HUP0203468A3 (en) Betha-d-5-thioxylose derivatives, preparation method and therapeutic use thereof
HUP0102116A3 (en) Paroxetine ascorbate, process for its preparation and its pharmaceutical use
ZA9811731B (en) Composition for treating respiratory and skin diseases
EP0998934A4 (en) REMEDIES AGAINST INTRAMEDULLARY DISEASES

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished
HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORP., US